TPO and autoimmune thrombocytopenic purpura: Withdrawing or pausing effective ITP therapy, such as TPO‐RAs, should be avoided due to the risk of rebound thrombocytopenia (C21, 78%), and the need to maintain a haemostatic platelet count during acute thrombotic events to enable appropriate antithrombotic treatment (C22, 85%).